{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:23:05Z","timestamp":1789831385649,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction\/Objectives<\/jats:title>\n                <jats:p>Ankylosing spondylitis (AS) is a chronic inflammatory immune-mediated condition. We compared AS diagnosis, treatment, and burden in Central Eastern European countries (CEE), where this has been less researched, and the United States (US) from a real-world perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Point-in-time survey of rheumatologists and their AS patients was conducted in the US (Apr\u2013Oct 2018) and CEE (Aug\u2013Nov 2019) via physician- and patient-completed record forms, including clinical and patient-reported outcomes. Statistical analysis included descriptive statistics, <jats:italic>t<\/jats:italic>-tests, Fisher\u2019s exact tests, and generalized linear models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 487 patients were recruited from 88 rheumatologists in the US and 922 patients from 126 rheumatologists in CEE. Time from onset of symptoms to final AS diagnosis was longer in CEE than the US (4.2 vs 2.7\u00a0years, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). At diagnosis, a greater use of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and injected steroids was reported in CEE vs the US (43.7% vs 27.6%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05; 19.3% vs 8.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). 22.9% of US patients received a biologic DMARD at diagnosis vs 10% of CEE patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). At current consultation, biologic DMARD use in CEE was lower vs the US (27.9% vs 71.0%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). CEE vs US patients had greater disease activity (mean Bath Ankylosing Spondylitis Disease Activity Index 4.2 vs 3.1, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and worse quality of life (QoL; mean Ankylosing Spondylitis Quality of Life Questionnaire score 6.2 vs 8.4, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AS patients in CEE vs the US faced slower diagnosis and worse access to biologics, disease activity, and QoL. Whether early access to biologics can improve symptoms, QoL, and daily activities in AS patients in CEE remains to be seen.<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>The study provided evidence on the real-world approach to the diagnosis, treatment, and burden of axSpA (axial spondyloarthritis) in CEE compared with the US.<\/jats:italic>\u2022 <jats:italic>The study reported patients in CEE experienced longer delays in diagnosis and poorer access to biologics than in the US.<\/jats:italic>\u2022 <jats:italic>This may have resulted in higher disease activity, greater levels of pain, and poorer outcomes, as reported by patients with axSpA in CEE.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-021-05864-8","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T06:02:51Z","timestamp":1627452171000},"page":"4915-4926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Investigating diagnosis, treatment, and burden of disease in patients with ankylosing spondylitis in Central Eastern Europe and the United States: a real-world study"],"prefix":"10.1007","volume":"40","author":[{"given":"T.","family":"Korotaeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Dina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Holdsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Meakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Vasilescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"issue":"1","key":"5864_CR1","first-page":"32","volume":"43","author":"K Erol","year":"2018","unstructured":"Erol K, Gok K, Cengiz G et al (2018) Extra-articular manifestations and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis. Acta Reumatol Port 43(1):32\u201339","journal-title":"Acta Reumatol Port"},{"issue":"4","key":"5864_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.semarthrit.2020.05.005","volume":"50","author":"GC Wright","year":"2020","unstructured":"Wright GC, Kaine J, Deodhar A (2020) Understanding differences between men and women with axial spondyloarthritis. Semin Arthritis Rheum 50(4):687\u2013694","journal-title":"Semin Arthritis Rheum"},{"issue":"10089","key":"5864_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73\u201384","journal-title":"Lancet"},{"issue":"6","key":"5864_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/acr.21621","volume":"64","author":"JD Reveille","year":"2012","unstructured":"Reveille JD, Witter JP, Weisman MH (2012) Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken) 64(6):905\u2013910","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"5864_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/BOR.0000000000000475","volume":"30","author":"R Wang","year":"2018","unstructured":"Wang R, Ward MM (2018) Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol 30(2):137\u2013143","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"5864_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.semarthrit.2014.10.009","volume":"44","author":"A Boonen","year":"2015","unstructured":"Boonen A, Sieper J, van der Heijde D et al (2015) The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum 44(5):556\u2013562","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"5864_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5864_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10067-018-4397-3","volume":"38","author":"A Danve","year":"2019","unstructured":"Danve A, Deodhar A (2019) Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities. Clin Rheumatol 38(3):625\u2013634","journal-title":"Clin Rheumatol"},{"issue":"7","key":"5864_CR9","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/art.39612","volume":"68","author":"A Deodhar","year":"2016","unstructured":"Deodhar A, Mease PJ, Reveille JD et al (2016) Frequency of axial spondyloarthritis diagnosis among patients seen by US rheumatologists for evaluation of chronic back pain. Arthritis Rheumatol 68(7):1669\u20131676","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"5864_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s10067-014-2768-y","volume":"34","author":"MR Seo","year":"2015","unstructured":"Seo MR, Baek HL, Yoon HH et al (2015) Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. Clin Rheumatol 34(8):1397\u20131405","journal-title":"Clin Rheumatol"},{"issue":"5","key":"5864_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11926-019-0819-8","volume":"21","author":"M Garrido-Cumbrera","year":"2019","unstructured":"Garrido-Cumbrera M, Poddubnyy D, Gossec L et al (2019) The European map of axial spondyloarthritis: capturing the patient perspective-an analysis of 2846 patients across 13 countries. Curr Rheumatol Rep 21(5):19","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"5864_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40744-020-00194-8","volume":"7","author":"E Yi","year":"2020","unstructured":"Yi E, Ahuja A, Rajput T et al (2020) Clinical, economic, and humanistic burden associated with delayed diagnosis of axial spondyloarthritis: a systematic review. Rheumatol Ther 7(1):65\u201387","journal-title":"Rheumatol Ther"},{"issue":"10","key":"5864_CR13","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS et al (2019) 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken) 71(10):1285\u20131299","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"5864_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991","journal-title":"Ann Rheum Dis"},{"key":"5864_CR15","doi-asserted-by":"publisher","first-page":"212556","DOI":"10.7573\/dic.212556","volume":"7","author":"D Opris-Belinski","year":"2018","unstructured":"Opris-Belinski D, Erdes SF, Grazio S et al (2018) Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries. Drugs Context 7:212556","journal-title":"Drugs Context"},{"key":"5864_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/PPA.S162420","volume":"12","author":"JC Torre-Alonso","year":"2018","unstructured":"Torre-Alonso JC, Queiro R, Comellas M et al (2018) Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. Patient Prefer Adherence 12:733\u2013747","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"5864_CR17","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N et al (2008) Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin 24(11):3063\u20133072","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"5864_CR18","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"issue":"4","key":"5864_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/rheumatology\/ker377","volume":"51","author":"JC Packham","year":"2012","unstructured":"Packham JC, Jordan KP, Haywood KL et al (2012) Evaluation of Ankylosing Spondylitis Quality of Life Questionnaire: responsiveness of a new patient-reported outcome measure. Rheumatology (Oxford) 51(4):707\u2013714","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5864_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1477-7525-6-94","volume":"7","author":"DK Whynes","year":"2008","unstructured":"Whynes DK (2008) Correspondence between EQ-5D health state classifications and EQ VAS scores. Health Qual Life Outcomes 7(6):94","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"5864_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"5864_CR22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","volume":"77","author":"U Kiltz","year":"2018","unstructured":"Kiltz U, van der Heijde D, Boonen A et al (2018) Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis 77(9):1311\u20131317","journal-title":"Ann Rheum Dis"},{"key":"5864_CR23","volume-title":"Statistical methods for research workers","author":"RA Fisher","year":"1934","unstructured":"Fisher RA (1934) Statistical methods for research workers, 5th edn. Oliver & Boyd, Edinburgh","edition":"5"},{"issue":"1\u20132","key":"5864_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/biomet\/38.1-2.141","volume":"38","author":"GH Freeman","year":"1951","unstructured":"Freeman GH, Halton JH (1951) Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 38(1\u20132):141\u2013149","journal-title":"Biometrika"},{"key":"5864_CR25","first-page":"427","volume":"78","author":"CR Mehta","year":"1983","unstructured":"Mehta CR, Patel NR (1983) A network algorithm for performing Fisher\u2019s exact test in rxc contingecy tables. Journal of the American Statistical Associaition 78:427\u2013434","journal-title":"Journal of the American Statistical Associaition"},{"key":"5864_CR26","doi-asserted-by":"crossref","unstructured":"McCullagh P, Nelder JA (1989) Generalized linear models: monographs on statistics and applied probability 37, 2nd edn. Chapman and Hall, London","DOI":"10.1007\/978-1-4899-3242-6"},{"key":"5864_CR27","unstructured":"Agresti A (2012) Categorical data analysis,\u00a03rd edn. John Wiley & Sons, Hoboken"},{"issue":"3","key":"5864_CR28","first-page":"19","volume":"13","author":"WH Rogers","year":"1994","unstructured":"Rogers WH (1994) Regression standard errors in clustered samples. Stata Technical Bulletin 13(3):19\u201323","journal-title":"Stata Technical Bulletin"},{"key":"5864_CR29","unstructured":"EphRMA (2020) European Pharmaceutical Market Research Association (EphMRA) code of conduct 2020. Available at https:\/\/www.ephmra.org\/standards\/code-of-conduct-aer\/"},{"issue":"3","key":"5864_CR30","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1136\/annrheumdis-2013-204867","volume":"74","author":"J S\u00f8rensen","year":"2015","unstructured":"S\u00f8rensen J, Hetland ML (2015) Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 74(3):e12","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5864_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13075-018-1724-7","volume":"20","author":"M Ar\u00e9valo","year":"2018","unstructured":"Ar\u00e9valo M, Gratac\u00f3s Masmitj\u00e0 J, Moreno M et al (2018) Influence of HLA-B27 on the ankylosing spondylitis phenotype: results from the REGISPONSER database. Arthritis Res Ther 20(1):221","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5864_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","volume":"18","author":"JJ de Winter","year":"2016","unstructured":"de Winter JJ, van Mens LJ, van der Heijde D et al (2016) Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther 18(1):196","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"5864_CR33","first-page":"465","volume":"22","author":"JL Fern\u00e1ndez-Sueiro","year":"2004","unstructured":"Fern\u00e1ndez-Sueiro JL, Alonso C, Blanco FJ et al (2004) Prevalence of HLA-B27 and subtypes of HLA-B27 associated with ankylosing spondylitis in Galicia. Spain. Clin Exp Rheumatol 22(4):465\u20138","journal-title":"Spain. Clin Exp Rheumatol"},{"issue":"1","key":"5864_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11136-019-02308-4","volume":"29","author":"G Rohde","year":"2020","unstructured":"Rohde G, Berg KH, Pripp AH et al (2020) No deterioration in health-related quality of life in patients with axial spondyloarthritis followed for 5 years in ordinary outpatient clinics in the biological treatment era. Qual Life Res 29(1):99\u2013107","journal-title":"Qual Life Res"},{"issue":"4","key":"5864_CR35","doi-asserted-by":"publisher","first-page":"Sr1","DOI":"10.12659\/MSM.881697","volume":"17","author":"E Orlewska","year":"2011","unstructured":"Orlewska E, Ancuta I, Anic B et al (2011) Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit 17(4):Sr1-13","journal-title":"Med Sci Monit"},{"issue":"Suppl 1","key":"5864_CR36","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1007\/s10198-014-0592-6","volume":"15","author":"M P\u00e9ntek","year":"2014","unstructured":"P\u00e9ntek M, Po\u00f3r G, Wiland P et al (2014) Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ 15(Suppl 1):S35-43","journal-title":"Eur J Health Econ"},{"key":"5864_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2019.00279","volume":"10","author":"DC Baumgart","year":"2019","unstructured":"Baumgart DC, Misery L, Naeyaert S et al (2019) Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol 10:279","journal-title":"Front Pharmacol"},{"issue":"3","key":"5864_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/rheumatology\/keu156","volume":"54","author":"EL Nasonov","year":"2015","unstructured":"Nasonov EL, Karateev DE (2015) Does Russia need a treat-to-target initiative? Rheumatology (Oxford) 54(3):381\u2013382","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5864_CR39","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3899\/jrheum.151244","volume":"43","author":"MJ Kviatkovsky","year":"2016","unstructured":"Kviatkovsky MJ, Ramiro S, Landew\u00e9 R et al (2016) The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis. J Rheumatol 43(9):1680\u20131686","journal-title":"J Rheumatol"},{"issue":"1","key":"5864_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/art.22469","volume":"57","author":"WP Maksymowych","year":"2007","unstructured":"Maksymowych WP, Richardson R, Mallon C et al (2007) Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum 57(1):133\u2013139","journal-title":"Arthritis Rheum"},{"key":"5864_CR41","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabases J (eds) (2014) Self-reported population health: an international perspective based on EQ-5D.\u00a0 Springer, Dordrecht","DOI":"10.1007\/978-94-007-7596-1"},{"issue":"3","key":"5864_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3899\/jrheum.160924","volume":"44","author":"M Di Carlo","year":"2017","unstructured":"Di Carlo M, Becciolini A, Lato V et al (2017) The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol 44(3):279\u2013285","journal-title":"J Rheumatol"},{"issue":"14","key":"5864_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12955-016-0463-1","volume":"17","author":"M Di Carlo","year":"2016","unstructured":"Di Carlo M, Lato V, Carotti M et al (2016) Clinimetric properties of the ASAS Health Index in a cohort of Italian patients with axial spondyloarthritis. Health Qual Life Outcomes 17(14):78","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"5864_CR44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/01.jom.0000166864.58664.29","volume":"47","author":"JJ Collins","year":"2005","unstructured":"Collins JJ, Baase CM, Sharda CE et al (2005) The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med 47(6):547\u2013557","journal-title":"J Occup Environ Med"}],"updated-by":[{"DOI":"10.1007\/s10067-022-06069-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05864-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05864-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05864-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T07:11:31Z","timestamp":1643353891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05864-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5864"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05864-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10067-022-06069-3","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-022-06069-3","URL":"https:\/\/doi.org\/10.1007\/s10067-022-06069-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The DSP\u2122 complies with all relevant market research guidelines and legal obligations. Data were collected according to European Pharmaceutical Marketing Research Association guidelines and thus did not require ethics committee approvals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Using a check box, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt by Adelphi Real World.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"TK received research grants from Pfizer, and consultancy\/speaking fees from Janssen, Pfizer, MCD, UCB, Novartis, Abbvie, Biocad, Lilly and Novartis-Sandoz.OD, LF, LW, RV, and JCC are employees of Pfizer Inc. and own stocks in Pfizer Inc.EH, GM, and SM are employees of Adelphi Real World. Adelphi Real World received funding from Pfizer Inc. for this analysis and manuscript development.AD received research grants and consultancy\/speaking fees from Pfizer Inc.; he has participated in advisory boards for Pfizer Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}